BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30590049)

  • 1. OX40 Regulates Both Innate and Adaptive Immunity and Promotes Nonalcoholic Steatohepatitis.
    Sun G; Jin H; Zhang C; Meng H; Zhao X; Wei D; Ou X; Wang Q; Li S; Wang T; Sun X; Shi W; Tian D; Liu K; Xu H; Tian Y; Li X; Guo W; Jia J; Zhang Z; Zhang D
    Cell Rep; 2018 Dec; 25(13):3786-3799.e4. PubMed ID: 30590049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling.
    Barrow F; Khan S; Fredrickson G; Wang H; Dietsche K; Parthiban P; Robert S; Kaiser T; Winer S; Herman A; Adeyi O; Mouzaki M; Khoruts A; Hogquist KA; Staley C; Winer DA; Revelo XS
    Hepatology; 2021 Aug; 74(2):704-722. PubMed ID: 33609303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
    Sutti S; Bruzzì S; Albano E
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD).
    Bruzzì S; Sutti S; Giudici G; Burlone ME; Ramavath NN; Toscani A; Bozzola C; Schneider P; Morello E; Parola M; Pirisi M; Albano E
    Free Radic Biol Med; 2018 Aug; 124():249-259. PubMed ID: 29920340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.
    Chackelevicius CM; Gambaro SE; Tiribelli C; Rosso N
    World J Gastroenterol; 2016 Nov; 22(41):9096-9103. PubMed ID: 27895397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role of OX40 in drug-induced acute liver injury.
    Zhang C; Jin H; Wang Y; Li C; Zhao X; Li Y; Shi W; Tian Y; Xu H; Tian D; Liu K; Jia J; Sun G; Zhang D
    Br J Pharmacol; 2020 Jul; 177(14):3183-3196. PubMed ID: 32133635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH).
    Jindal A; Bruzzì S; Sutti S; Locatelli I; Bozzola C; Paternostro C; Parola M; Albano E
    Exp Mol Pathol; 2015 Aug; 99(1):155-62. PubMed ID: 26112094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IQGAP1 restrains T-cell cosignaling mediated by OX40.
    Okuyama Y; Nagashima H; Ushio-Fukai M; Croft M; Ishii N; So T
    FASEB J; 2020 Jan; 34(1):540-554. PubMed ID: 31914585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal-Associated Invariant T Cells Improve Nonalcoholic Fatty Liver Disease Through Regulating Macrophage Polarization.
    Li Y; Huang B; Jiang X; Chen W; Zhang J; Wei Y; Chen Y; Lian M; Bian Z; Miao Q; Peng Y; Fang J; Wang Q; Tang R; Gershwin ME; Ma X
    Front Immunol; 2018; 9():1994. PubMed ID: 30233587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
    Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
    Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis.
    Tomita K; Freeman BL; Bronk SF; LeBrasseur NK; White TA; Hirsova P; Ibrahim SH
    Sci Rep; 2016 Jun; 6():28786. PubMed ID: 27349927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis.
    Chen Y; Tian Z
    Front Immunol; 2020; 11():1500. PubMed ID: 32765518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OX40 promotes obesity-induced adipose inflammation and insulin resistance.
    Liu B; Yu H; Sun G; Sun X; Jin H; Zhang C; Shi W; Tian D; Liu K; Xu H; Li X; Yin J; Hong X; Zhang D
    Cell Mol Life Sci; 2017 Oct; 74(20):3827-3840. PubMed ID: 28612217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis.
    Maricic I; Marrero I; Eguchi A; Nakamura R; Johnson CD; Dasgupta S; Hernandez CD; Nguyen PS; Swafford AD; Knight R; Feldstein AE; Loomba R; Kumar V
    J Immunol; 2018 Nov; 201(10):3017-3035. PubMed ID: 30322964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OX40 expression in neutrophils promotes hepatic ischemia/reperfusion injury.
    Jin H; Zhang C; Sun C; Zhao X; Tian D; Shi W; Tian Y; Liu K; Sun G; Xu H; Zhang D
    JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31672934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis.
    Dywicki J; Buitrago-Molina LE; Noyan F; Davalos-Misslitz AC; Hupa-Breier KL; Lieber M; Hapke M; Schlue J; Falk CS; Raha S; Prinz I; Koenecke C; Manns MP; Wedemeyer H; Hardtke-Wolenski M; Jaeckel E
    Hepatol Commun; 2022 Feb; 6(2):320-333. PubMed ID: 34532981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive immunity: an emerging player in the progression of NAFLD.
    Sutti S; Albano E
    Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):81-92. PubMed ID: 31605031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.